Northwestern Mutual Wealth Management Co. Acquires 13,252 Shares of Gilead Sciences, Inc. $GILD

Northwestern Mutual Wealth Management Co. increased its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 14.9% during the fourth quarter, Holdings Channel.com reports. The firm owned 102,074 shares of the biopharmaceutical company’s stock after buying an additional 13,252 shares during the period. Northwestern Mutual Wealth Management Co.’s holdings in Gilead Sciences were worth $12,529,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Ares Financial Consulting LLC bought a new position in shares of Gilead Sciences during the fourth quarter valued at approximately $28,000. Financial Consulate Inc. boosted its stake in shares of Gilead Sciences by 85.8% during the fourth quarter. Financial Consulate Inc. now owns 236 shares of the biopharmaceutical company’s stock valued at $29,000 after purchasing an additional 109 shares in the last quarter. North Star Investment Management Corp. boosted its stake in shares of Gilead Sciences by 54.8% during the fourth quarter. North Star Investment Management Corp. now owns 243 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 86 shares in the last quarter. MTM Investment Management LLC boosted its stake in shares of Gilead Sciences by 176.0% during the third quarter. MTM Investment Management LLC now owns 276 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 176 shares in the last quarter. Finally, BOCHK Asset Management Ltd bought a new position in shares of Gilead Sciences during the fourth quarter valued at approximately $31,000. 83.67% of the stock is currently owned by institutional investors.

Gilead Sciences Price Performance

Shares of GILD opened at $130.50 on Friday. The company has a market cap of $162.02 billion, a price-to-earnings ratio of 17.78 and a beta of 0.31. Gilead Sciences, Inc. has a twelve month low of $104.46 and a twelve month high of $157.29. The company has a quick ratio of 1.77, a current ratio of 1.97 and a debt-to-equity ratio of 0.89. The company has a 50 day moving average of $136.50 and a two-hundred day moving average of $133.64.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share for the quarter, beating the consensus estimate of $1.91 by $0.12. The company had revenue of $6.96 billion during the quarter, compared to the consensus estimate of $6.91 billion. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. Gilead Sciences’s revenue was up 4.4% compared to the same quarter last year. During the same period last year, the firm earned $1.81 earnings per share. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. As a group, analysts predict that Gilead Sciences, Inc. will post -0.77 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, June 29th. Investors of record on Monday, June 15th will be given a $0.82 dividend. This represents a $3.28 annualized dividend and a dividend yield of 2.5%. The ex-dividend date of this dividend is Monday, June 15th. Gilead Sciences’s dividend payout ratio is presently 44.69%.

Trending Headlines about Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Maxim Group upgraded Gilead to Buy from Hold and raised its price target to $165, implying meaningful upside from current levels. Maxim Group upgrades Gilead Sciences (GILD)
• Positive Sentiment: Gilead completed its acquisition of Tubulis GmbH, adding next-generation antibody-drug conjugate assets that strengthen its oncology pipeline and could expand future growth opportunities. Gilead Sciences Completes Acquisition of Tubulis Further Strengthening Oncology Portfolio
• Positive Sentiment: New ASCO and EHA 2026 data and upcoming presentations highlight continued momentum in Gilead and Kite’s oncology programs, including antibody-drug conjugates and cell therapy. New ASCO and EHA 2026 Data Demonstrate Gilead and Kite’s Momentum Across Antibody-Drug Conjugates and Cell Therapy in Oncology
• Positive Sentiment: Gilead also expanded its collaboration with the World Health Organization to help eliminate visceral leishmaniasis, reinforcing its public-health commitment and corporate reputation. Gilead Sciences and World Health Organization Expand Collaboration to Help Eliminate Visceral Leishmaniasis
• Neutral Sentiment: Several articles highlighted Gilead as a profitable large-cap biotech with strong margins and analyst interest, which may support the stock, but these were largely commentary pieces rather than new fundamental catalysts. Gilead Sciences (GILD) Is Among The Best Extremely Profitable Stocks To Buy According To Wall Street Analysts
• Neutral Sentiment: Gilead launched $3 billion in senior notes, a financing move that is not necessarily negative but may weigh on some investors’ view of leverage and interest expense. Gilead Sciences Launches New $3 Billion Senior Notes
• Negative Sentiment: One earnings-call summary pointed to “deal drag,” suggesting some investors may be focused on near-term integration or transaction costs that could temper enthusiasm despite solid overall results. Gilead Sciences Earnings Call Highlights Growth, Deal Drag

Insider Activity at Gilead Sciences

In related news, CEO Daniel Patrick O’day sold 10,000 shares of the company’s stock in a transaction on Tuesday, April 28th. The stock was sold at an average price of $129.16, for a total value of $1,291,600.00. Following the transaction, the chief executive officer directly owned 632,567 shares of the company’s stock, valued at $81,702,353.72. This represents a 1.56% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of the company’s stock in a transaction on Friday, May 15th. The shares were sold at an average price of $132.27, for a total value of $396,810.00. Following the completion of the transaction, the chief financial officer directly owned 173,191 shares in the company, valued at approximately $22,907,973.57. The trade was a 1.70% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 63,000 shares of company stock valued at $8,523,570 in the last ninety days. Company insiders own 0.30% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on GILD shares. UBS Group increased their price objective on shares of Gilead Sciences from $145.00 to $155.00 and gave the company a “buy” rating in a research note on Monday, January 26th. Oppenheimer increased their price objective on shares of Gilead Sciences from $128.00 to $165.00 and gave the company an “outperform” rating in a research note on Wednesday, February 11th. Morgan Stanley lowered their target price on shares of Gilead Sciences from $175.00 to $168.00 in a research note on Friday, May 8th. Sanford C. Bernstein restated an “outperform” rating and issued a $160.00 target price on shares of Gilead Sciences in a research note on Wednesday, February 11th. Finally, Deutsche Bank Aktiengesellschaft raised their target price on shares of Gilead Sciences from $135.00 to $155.00 and gave the company a “buy” rating in a research note on Wednesday, February 11th. Twenty-five analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat.com, Gilead Sciences presently has an average rating of “Moderate Buy” and an average price target of $156.93.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.